| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab175529-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $69.90 | |
| Ab175529-1mg | 1mg | In stock | $319.90 | |
| Ab175529-5mg | 5mg | In stock | $779.90 | |
| Ab175529-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,239.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Enoblituzumab (anti-CD276) - Primary antibody, specific to CD276, >95%, high purity, Human IgG1 |
|---|---|
| Synonyms | 4Ig B7 H3 antibody | 4Ig-B7-H3 antibody | AU016588 antibody | B7 H3 antibody | B7 homolog 3 antibody | B7-H3 antibody | B7H3 antibody | B7RP-2 antibody | CD_antigen=CD276 antibody | CD276 antibody | CD276 antigen antibody | CD276 molecule antibody | CD276 |
| Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
| Host species | Human |
| Specificity | CD276 |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | CROSS-LINKING AGENT |
| Mechanism of action | Antibody of B7-H3 (CD276) |
| Product Description | Enoblituzumab (anti-CD276) is a humanized IgG1κ monoclonal antibody recognizing human B7-H3 protein, a member of the B7 family of immune regulators. |
| Isotype | Human IgG1 |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 26.7 kDa (Light Chain) & 51.2 kDa (Heavy Chain), under reducing conditions; 182.0 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Purity | >95% |
| Form | Liquid |
| Concentration | Lot by Lot |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 1353485-38-7 |
Enoblituzumab (anti-CD276) (Ab175529) - Flow Cytometry
Flow Cytometry analysis of MCF-7 cells labelling CD276 (red) with Enoblituzumab (anti-CD276) (Ab175529). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Enoblituzumab (anti-CD276) (Ab175529) - Flow Cytometry
Flow Cytometry analysis of HEK-293 cells labelling CD276 (red) with Enoblituzumab (anti-CD276) (Ab175529). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Enoblituzumab (anti-CD276) (Ab175529) - SEC
The purity of Enoblituzumab (anti-CD276) (Ab175529) is more than 95% verified by HPLC.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| IMGT/mAb-DB | 590 |
|---|
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ23F1202015 | Certificate of Analysis | Dec 13, 2023 | Ab175529 |
| ZJ23F1202016 | Certificate of Analysis | Dec 13, 2023 | Ab175529 |
| 1. Loo D, Alderson RF, Chen FZ, Huang L, Zhang W, Gorlatov S, Burke S, Ciccarone V, Li H, Yang Y et al.. (2012) Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity.. Clin Cancer Res, 18 (14): (3834-45). [PMID:22615450] [10.1021/op500134e] |
| 2. Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, Dong H, Sica GL, Zhu G, Tamada K et al.. (2001) B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production.. Nat Immunol, 2 (3): (269-74). [PMID:11224528] [10.1021/op500134e] |
| 3. Castriconi R, Dondero A, Augugliaro R, Cantoni C, Carnemolla B, Sementa AR, Negri F, Conte R, Corrias MV, Moretta L et al.. (2004) Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis.. Proc Natl Acad Sci USA, 101 (34): (12640-5). [PMID:15314238] [10.1021/op500134e] |
| 4. Ling, Vincent V and 6 more authors.. (2003) Duplication of primate and rodent B7-H3 immunoglobulin V- and C-like domains: divergent history of functional redundancy and exon loss.. Genomics, [PMID:12906861] |
| 5. Steinberger, Peter P and 9 more authors.. (2004) Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains.. Journal of immunology (Baltimore, Md. : 1950), (15): [PMID:14764704] |
| 6. Wang, Liqing L and 7 more authors.. (2005) B7-H3 promotes acute and chronic allograft rejection.. European journal of immunology, [PMID:15682454] |
| 7. Kim, Jean J and 8 more authors.. (2005) Constitutive and inducible expression of b7 family of ligands by human airway epithelial cells.. American journal of respiratory cell and molecular biology, [PMID:15961727] |
| 8. Petroff, Margaret G MG, Kharatyan, Elza E, Torry, Donald S DS and Holets, Lesya L.. (2005) The immunomodulatory proteins B7-DC, B7-H2, and B7-H3 are differentially expressed across gestation in the human placenta.. The American journal of pathology, [PMID:16049332] |
| 9. Zhang, Guangbo G, Dong, Qiuming Q, Xu, Ying Y, Yu, Gehua G and Zhang, Xueguang X.. (2005) B7-H3: another molecule marker for Mo-DCs?. Cellular & molecular immunology, [PMID:16274630] |
| 10. Otsuki, Tetsuji T and 24 more authors.. (2005) Signal sequence and keyword trap in silico for selection of full-length human cDNAs encoding secretion or membrane proteins from oligo-capped cDNA libraries.. DNA research : an international journal for rapid publication of reports on genes and genomes, [PMID:16303743] |
| 11. Hashiguchi, Masaaki M and 5 more authors.. (2008) Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses.. Proceedings of the National Academy of Sciences of the United States of America, (29): [PMID:18650384] |
